Key Takeaway: SAB Biotherapeutics, a clinical-stage biopharmaceutical company, will host a conference call on August 6, 2026, to discuss its second quarter financial results. The call is aimed at providing investors with updates on the company's developments, particularly in its efforts to treat type 1 diabetes and other autoimmune diseases. This event highlights the company's commitment to transparency and investor engagement.
Price reaction · baseline $3.48 (2026-07-29 close) · hit pre-market · clean, no other SABS news in the window
day 0 close · peak
+2.3%
Market Sentiment Analysis
POSITIVE FACTORS
SAB Biotherapeutics is actively engaging with investors.
The conference call will provide insights into financial results.
The company is focused on developing innovative treatments for autoimmune diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
25.7%
average across 4 past catalysts
Cash runway
~31 mo
Minimal dilution risk
Lead asset
SAB-142
Phase 3 · Type 1 Diabetes (T1D)
Full Press Release Details
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its second quarter 2026
Frequently Asked Questions
When is the SAB Biotherapeutics Q2 2026 call?
The call is scheduled for August 6, 2026, at 08:30 AM ET.
What will be discussed in the conference call?
The call will cover SAB Biotherapeutics' second quarter financial results.
What is SAB Biotherapeutics developing?
The company is developing a fully human anti-thymocyte immunoglobulin for type 1 diabetes.
Where can I access the webcast?
Details for accessing the webcast will be provided in the announcement.